REVOLADE  25MG    

Description                                     

Revolade tablets included Eltrombopag olamine, a small molecule thrombopoietin (TPO) receptor agonist for oral administration. Revolade interacts with the transmembrane domain of the TPO receptor (also known as cMpl) causes to increased platelet production.

Revolade 25mg is a prescription drug which is used under the guidance of the doctor

Indication

Revolade 25mg is mainly indicated for the treatment of patients having Severe aplastic Anemia

• First line treatment of severe aplastic Anemia
• Treatment of refractory severe aplastic Anemia

Revolade 25mg is indicated for the treatment to stimulate the growth and development of platelets in the bone marrow

Revolade 25mg is mainly indicated for the treatment of patients having reduced platelet counts due to chronic hepatitis C virus infection

Mechanism of action

Small-molecule thrombopoietin (TPO)-receptor agonist whichconcomitant with human TPO receptor transmembrane domain of human TPO-receptor &startsindicating cascades that encouragereplication& differentiation of megakaryocytes from bone marrow forebear cells

ADME Properties

Peak plasma concentration is 2-6 hours

highly human plasma protein bounding is >99% and in blood plasma level is 50% to 79%

predominantly metabolised through cleavage, oxidation and conjugation with glucuronic acid.

Revolade 25mg eliminated primarily via feces 59%, along with 31% via renally excreted

Half-life of Revolade 25mg healthy patients is 21-23 hours and idiopathic thrombocytopenic purpura is 26-35 hours.

Dosage and administration

Chronic Hepatitis C-associated Thrombocytopenia

The recommended dose: 25 mg PO qDay

Dose is Adjust in 25 mg accretion q2weeks PRN to attain target Pltneeded to start/control antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day

Severe Aplastic Anemia

1.First-line therapy:

Concomitant use with standard immunosuppressive therapy, for patients with serious aplastic Anemia (SAA)

The recommended dose: 150 mg PO qDay for 6 months

Do not give more thanstarting dose; total duration is 6 months

2.Refractory SAA:

The drug given for this condition who fail to respond enough to at least 1 before immunosuppressive therapy

The recommended dose: 50 mg PO qDay

Chronic Immune Thrombocytopenia:

The recommended dose: 50 mg PO qDay

Adjust dose to achieve and control platelet count (Plt) >50 x 10^9/L to lowers risk of bleeding; not to exceed 75 mg/day

Side effects

Common side effects of Revolade 25mg

• pain in head
• cough
• decreased appetite
• flu
• low red blood cells
• diarrhoea
• nausea
• fever
• weakness

Serious side effectsof Revolade 25mg

• Cloudy vision
• Urine in dark colour
• Yellowing of your skin
• Sensitivity to light
• Seeing circles around lights
• Swelling of legs
• Abdomen swelling
• Confusion
• Chest pain
• Dyspnea

Drug interaction

Concomitant use with Cholesterol-reducing drugs like atorvastatin, fluvastatin, rosuvastatin, pravastatin, and simvastatin, pitavastatin combination with Revolade 25mg. Have high side effects can contains muscle pain. The doctor may reduce the dosage of your cholesterol drugs.

These Revolade 25mg ezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan combination with Revolade 25mg will increase of side effects. Therefore, the doctor may decrease your dosage of these drugs if needed.

Antacids, vitamins, or supplements which involves Ca, Al, Fe, Se, Zn, or Mg interaction with Revolade 25mg. To stop interactions, then take Revolade two hours before or four hours after administrating any of these products.

Precautions

If the patients have cataracts, avoid the drug due to the Revolade 25mg effects cataracts and make the condition worse.

Do not using the Revolade 25mg while the patients have myelodysplastic syndrome (MDS), will increases the risk of death.

If other blood clot risk factors, then avoid the drug because it will increase platelet counts and blood clots.

Pregnancy

Pregnancy category is C

Animal studies admit the risk and human studies not available or neither animal nor human studies done. Use the Revolade 25mg with caution if asset outweigh risks

Lactation

The Revolade 25mg is not recommended during breast feeding

Storage

Store at room temperature 20⁰C and 25⁰ C.

Missed dose

In case of missed dose, patients must consult with medical practitioner and follow the instructions given by them.

thereby missed dose should be avoid and follow the regular dosing schedule.